ZITHROMAX is a macrolide antibacterial drug indicated for the treatment of the following infections caused by designated susceptible microorganisms:

•

Community-acquired pneumonia in adults (1.1)

•

Pelvic inflammatory disease in adults (1.2)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX and other antibacterial drugs, ZITHROMAX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.3)

•

Recommended Dosage for Community-acquired pneumonia: 500 mg as a single daily dose by the intravenous route for at least two days. (2.1)

•

Recommended Dosage for Pelvic inflammatory disease in adults: 500 mg as a single daily dose by the intravenous route for one or two days. (2.2)

ZITHROMAX for injection is supplied as white to off-white lyophilized powder in a single-dose vial equivalent to 500 mg of azithromycin for intravenous administration. (3)

•

Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide antibacterial drug. (4.1)

•

Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. (4.2)

•

Serious (including fatal) allergic and skin reactions. Discontinue ZITHROMAX and initiate appropriate therapy if reaction occurs. (5.1)

•

Hepatotoxicity: Severe and sometimes fatal, hepatoxicity has been reported. Discontinue ZITHROMAX immediately if signs and symptoms of hepatitis occur. (5.2)

•

Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs. (5.3)

•

Prolongation of QT interval and cases of torsades de pointes have been reported. This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (5.4)

•

Cardiovascular Death: Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. Consider balancing this potential risk with treatment benefits when prescribing ZITHROMAX. (5.5)

•

Clostridioides difficile-Associated Diarrhea: Evaluate patients if diarrhea occurs. (5.6)

•

ZITHROMAX may exacerbate muscle weakness in persons with myasthenia gravis. (5.7)

Most common adverse reactions are nausea (4%), diarrhea (4%), abdominal pain (3%), or vomiting (1%). (6)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

•

Nelfinavir: Close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. (7.1)

•

Warfarin: Use with azithromycin may increase coagulation times; monitor prothrombin time. (7.2)

•

Geriatric use: Elderly patients may be more susceptible to development of torsades de pointes arrhythmias. (8.5)